Increased airway hyperresponsiveness to adenosine in patients with aspirin intolerant asthma | Zendy

Sumito Isogai | Zendy; Yoshikazu Niwa | Zendy; Hiroshi Yatsuya | Zendy; Masamichi Hayashi | Zendy; Naoki Yamamoto | Zendy; Takuya Okamura | Zendy; Tomoyuki Minezawa | Zendy; Yasuhiro Gotô | Zendy; Teppei Yamaguchi | Zendy; Tomoko Takeyama | Zendy; Yosuke Sakakibara | Zendy; Sayako Morikawa | Zendy; Tomoya Horiguchi | Zendy; Yusuke Gotoh | Zendy; Yuki Mieno | Zendy; Sakurako Uozu | Zendy; Toru Nakanishi | Zendy; Mitsushi Okazawa | Zendy; Hiroki Sakakibara | Zendy; Kazuyoshi Imaizumi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Increased airway hyperresponsiveness to adenosine in patients with aspirin intolerant asthma

Author(s) -

Sumito Isogai,

Yoshikazu Niwa,

Hiroshi Yatsuya,

Masamichi Hayashi,

Naoki Yamamoto,

Takuya Okamura,

Tomoyuki Minezawa,

Yasuhiro Gotô,

Teppei Yamaguchi,

Tomoko Takeyama,

Yosuke Sakakibara,

Sayako Morikawa,

Tomoya Horiguchi,

Yusuke Gotoh,

Yuki Mieno,

Sakurako Uozu,

Toru Nakanishi,

Mitsushi Okazawa,

Hiroki Sakakibara,

Kazuyoshi Imaizumi

Publication year - 2016

Publication title -

allergology international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.49

H-Index - 58

eISSN - 1440-1592

pISSN - 1323-8930

DOI - 10.1016/j.alit.2016.10.001

Subject(s) - airway hyperresponsiveness , medicine , asthma , aspirin , adenosine , airway , anesthesia

Age (mean ± SD) 42.6 ± 17.0 42.1 ± 14.9 n.s. Male 4 5 n.s. Atopy (þ/ ) 6/3 12/6 n.s. Severity (mild/moderate) 5/7 7/10 n.s. FVC (ml, mean ± SD) 3006 ± 586 3085 ± 722 n.s. FEV1.0 (ml, mean ± SD) 2430 ± 537 2365 ± 602 n.s. FEV1.0% (%, mean ± SD) 81.4 ± 9.2 77.2 ± 6.8 n.s. %FEV1.0 (%, mean ± SD) 90.3 ± 14.3 85.5 ± 13.3 n.s. WBC (/ml, mean ± SD) 6300 ± 1500 6900 ± 2200 n.s. Eosinophil (%, mean ± SD) 9.2 ± 6.3 6.5 ± 2.9 n.s. IgE (U/ml, mean ± SD) 285.5 ± 272.4 421.3 ± 404.9 n.s. Therapy n.s. ICS (mg, mean ± SD) 420 ± 261 360 ± 214 n.s. LABA (n) 6 5 n.s. Theophylline (n) 9 13 n.s. Dear Editor,

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research